TY - JOUR
T1 - Repetitive transcranial magnetic stimulation for smoking cessation
T2 - a pivotal multicenter double-blind randomized controlled trial
AU - Zangen, Abraham
AU - Moshe, Hagar
AU - Martinez, Diana
AU - Barnea-Ygael, Noam
AU - Vapnik, Tanya
AU - Bystritsky, Alexander
AU - Duffy, Walter
AU - Toder, Doron
AU - Casuto, Leah
AU - Grosz, Moran Lipkinsky
AU - Nunes, Edward V.
AU - Ward, Herbert
AU - Tendler, Aron
AU - Feifel, David
AU - Morales, Oscar
AU - Roth, Yiftach
AU - Iosifescu, Dan V
AU - Winston, Jaron
AU - Wirecki, Theodore
AU - Stein, Ahava
AU - Deutsch, Frederic
AU - Li, Xingbao
AU - George, Mark S.
N1 - Publisher Copyright: © 2021 World Psychiatric Association
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation method increasingly used to treat psychiatric disorders, primarily depression. Initial studies suggest that rTMS may help to treat addictions, but evaluation in multicenter randomized controlled trials (RCTs) is needed. We conducted a multicenter double-blind RCT in 262 chronic smokers meeting DSM-5 criteria for tobacco use disorder, who had made at least one prior failed attempt to quit, with 68% having made at least three failed attempts. They received three weeks of daily bilateral active or sham rTMS to the lateral prefrontal and insular cortices, followed by once weekly rTMS for three weeks. Each rTMS session was administered following a cue-induced craving procedure, and participants were monitored for a total of six weeks. Those in abstinence were monitored for additional 12 weeks. The primary outcome measure was the four-week continuous quit rate (CQR) until Week 18 in the intent-to-treat efficacy set, as determined by daily smoking diaries and verified by urine cotinine measures. The trial was registered at ClinicalTrials.gov (NCT02126124). In the intent-to-treat analysis set (N=234), the CQR until Week 18 was 19.4% following active and 8.7% following sham rTMS (X2=5.655, p=0.017). Among completers (N=169), the CQR until Week 18 was 28.0% and 11.7%, respectively (X2=7.219, p=0.007). The reduction in cigarette consumption and craving was significantly greater in the active than the sham group as early as two weeks into treatment. This study establishes a safe treatment protocol that promotes smoking cessation by stimulating relevant brain circuits. It represents the first large multicenter RCT of brain stimulation in addiction medicine, and has led to the first clearance by the US Food and Drug Administration for rTMS as an aid in smoking cessation for adults.
AB - Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation method increasingly used to treat psychiatric disorders, primarily depression. Initial studies suggest that rTMS may help to treat addictions, but evaluation in multicenter randomized controlled trials (RCTs) is needed. We conducted a multicenter double-blind RCT in 262 chronic smokers meeting DSM-5 criteria for tobacco use disorder, who had made at least one prior failed attempt to quit, with 68% having made at least three failed attempts. They received three weeks of daily bilateral active or sham rTMS to the lateral prefrontal and insular cortices, followed by once weekly rTMS for three weeks. Each rTMS session was administered following a cue-induced craving procedure, and participants were monitored for a total of six weeks. Those in abstinence were monitored for additional 12 weeks. The primary outcome measure was the four-week continuous quit rate (CQR) until Week 18 in the intent-to-treat efficacy set, as determined by daily smoking diaries and verified by urine cotinine measures. The trial was registered at ClinicalTrials.gov (NCT02126124). In the intent-to-treat analysis set (N=234), the CQR until Week 18 was 19.4% following active and 8.7% following sham rTMS (X2=5.655, p=0.017). Among completers (N=169), the CQR until Week 18 was 28.0% and 11.7%, respectively (X2=7.219, p=0.007). The reduction in cigarette consumption and craving was significantly greater in the active than the sham group as early as two weeks into treatment. This study establishes a safe treatment protocol that promotes smoking cessation by stimulating relevant brain circuits. It represents the first large multicenter RCT of brain stimulation in addiction medicine, and has led to the first clearance by the US Food and Drug Administration for rTMS as an aid in smoking cessation for adults.
KW - Smoking cessation
KW - addiction medicine
KW - cigarette consumption
KW - cigarette craving
KW - insula
KW - lateral prefrontal cortex
KW - repetitive transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85114695459&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/wps.20905
DO - https://doi.org/10.1002/wps.20905
M3 - Article
SN - 1723-8617
VL - 20
SP - 397
EP - 404
JO - World Psychiatry
JF - World Psychiatry
IS - 3
ER -